1133: 10 Years High Intensity Focused Ultrasound (HIFU) as Local Treatment of Prostate Cancer: Profile of Side Effects

Thueroff, S.; Knauer, K.; Chaussy, C.

doi:10.1016/s0022-5347(18)33358-5

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it was decided for this review to focus on HIFU as primary therapy for prostate cancer. Considering this, 25 articles/ abstracts evaluating HIFU with the Ablatherm [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][35][36][37][38][39][40][41] and five with the Sonablate device were selected [23][24][25][26][27].…”

Section: Resultsmentioning

confidence: 99%

“…In all, 37 articles/abstracts of studies evaluating the efficacy and/or safety of HIFU in prostate cancer were selected [5–41]. Data on HIFU as salvage therapy after RT were limited; only two fully published papers and five abstracts were identified [28–34].…”

Section: Resultsmentioning

confidence: 99%

“…Two studies evaluating the Ablatherm device suggested that HIFU re‐treatment might increase the risk of several complications, e.g. SUI, UTI, ED and recto‐urethral fistula [35,38,39].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

Rébillard¹,

Soulié²,

Chartier‐Kastler

et al. 2008

BJU International

103

View full text Add to dashboard Cite

antigen (PSA) level of ≤ 28 ng/mL and a prostate volume of ≤ 40 mL. Negative biopsy rates with the Ablatherm TM device (EDAP TMS S.A., Vaulx-en-Velin, France) were 64-93%, and a PSA nadir of ≤ 0.5 ng/mL was achieved in 55-84% of patients. The 5-year actuarial disease-free survival rates were 60-70%. The most common complications were stress urinary incontinence, urinary tract infection, urethral/bladder neck stenosis or strictures, and erectile dysfunction. For the Ablatherm device, the rate of complications has been significantly reduced over the years, due to technical improvements in the device and the use of transurethral resection of the prostate before HIFU. In conclusion, HIFU as primary therapy for prostate cancer is indicated in older patients ( ≥ 70 years) with T1-T2 N0M0 disease, a Gleason score of < 7, a PSA level of < 15 ng/mL and a prostate volume of < 40 mL. In these patients HIFU achieves short-term cancer control, as shown by a high percentage of negative biopsies and significantly reduced PSA levels. The median-term survival data also seem promising, but long-term follow-up studies are needed to further evaluate cancerspecific and overall survival rates before the indications for primary therapy can be expanded.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

Rébillard¹,

Soulié²,

Chartier‐Kastler

et al. 2008

BJU International

103

View full text Add to dashboard Cite

show abstract

“…The most common complications of HIFU are urine tract infections, stress incontinence, urine flow obstruction, rectal burn, rectal discomfort and fistula (24)(25)(26). The severity of these complications decreased significantly after the learning curve and the evolution of the used techniques.…”

Section: Hifumentioning

confidence: 99%

HIFU and cryoablation – non or minimal touch techniques for the treatment of prostate cancer. Is there a role for contrast enhanced ultrasound?

Wondergem¹,

Rosette²

2007

Minimally Invasive Therapy & Allied Technologies

View full text Add to dashboard Cite

The incidence of prostate cancer is increasing, and therefore also the need for optimal treatment. Because of the appearance of many different disease stages different treatment modalities are desirable for the treatment of localized prostate cancer. The established therapies, radical prostatectomy and radiation therapy, are associated with a lot of risks, complications and co-morbidity, and not all patients are eligible for these treatments. That is why the need for reliable minimally invasive alternatives has developed. For this paper a literature search was conducted on published studies and review articles to determine the role of HIFU (high intensity focused ultrasound) and cryoablation as minimally invasive treatment modalities for localized prostate cancer. Both therapies are being used as a primary or secondary (salvage) treatment, but can they replace surgery or radiation? And is there a role for contrast enhanced ultrasound (CEUS) of the prostate to improve diagnostics, treatment outcomes and follow-up? To date the outcomes of both therapies are promising but no prospective and comparative randomized studies with a long term follow-up were available for analysis. From this review we can conclude that until those studies are available, HIFU and cryoablation are good alternatives for patients not eligible for prostatectomy or radiation. They should not be used as a first treatment option as long as diagnostics and follow-up have not improved.

show abstract

Erectile Dysfunction in Salvage Prostate Cancer Therapies

Sandher

Shabbir

2020

Salvage Therapy for Prostate Cancer

View full text Add to dashboard Cite

1133: 10 Years High Intensity Focused Ultrasound (HIFU) as Local Treatment of Prostate Cancer: Profile of Side Effects

Cited by 5 publications

References 0 publications

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

HIFU and cryoablation – non or minimal touch techniques for the treatment of prostate cancer. Is there a role for contrast enhanced ultrasound?

Erectile Dysfunction in Salvage Prostate Cancer Therapies

Contact Info

Product

Resources

About